Bringing the fundamentals into focus…
Back to Supernus Pharmaceuticals, Inc.
How Supernus Pharmaceuticals, Inc. stacks up
SUPN · against 404 other Healthcare companies of similar size
Growth
50/ 100
Below the middle of the pack.
Ranked #206 of 405 · scores higher than 48% of peers
Bars: peers in each 10-point band of the growth score34 peers with a growth score of 50–59, including SUPN · Click a bar to see the companies
Why growth scores 50?
Weighted metrics compared with all Healthcare companies.A mix: stronger revenue growth and 3-year revenue growth, but weaker earnings per share growth than most Healthcare peers.
- Earnings per share turned from a profit to a loss. Earnings per share growth: — vs peer median 9.8%
- faster revenue growth over three years: stronger than 61% of peers. 3-year revenue growth: 9.4% vs peer median 5.8%
- faster revenue growth over the last year: stronger than 83% of peers. Revenue growth: 24.9% vs peer median 6.1%
Metric by metric
Position: dot = SUPN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SUPN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 408 reported | 24.9% | 6.2% | 84% | 33% | |
| Earnings per share growthHigher is better · 223 reported | Not reported | 9.8% | — | — | 33% |
| 3-year revenue growthHigher is better · 396 reported | 9.4% | 6.9% | 56% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around SUPN| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 1 | 1.4B USD | 99 | 73 | |
| 1 | 27.6B SEK (≈$2.8B) | 99 | 76 | |
| 1 | 2.1B USD | 99 | 96 | |
| 1 | 2.8B USD | 99 | 51 | |
| 206 | 10.0B CNY (≈$1.4B) | 50 | 58 | |
| 206 | 12.0B SEK (≈$1.2B) | 50 | 72 | |
| 206 | 21.1B ZAR (≈$1.2B) | 50 | 60 | |
| 206 | 3.0B USD | 50 | 39 | |
| 206 | 1.6B USD | 50 | 48 | |
| 211 | 11.6B HKD (≈$1.5B) | 49 | 36 | |
| 211 | 6.8B HKD (≈$867M) | 49 | 56 | |
| 211 | 17.9B ZAR (≈$986M) | 49 | 62 | |
| 214 | 18.5B CNY (≈$2.6B) | 48 | 37 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score